Featured Trial:
Melanoma Treatment

Featured Trial:
Head and Neck Cancer Treatment

Featured Trial:
Breast Cancer Treatment

Featured Trial:
Sarcoma Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

April 4, 2024

Categories

The Spring 2024 advocacy blog Considering Clinical Trials is now available

April 3, 2024

Categories

Press Releases

Press Release: ECOG-ACRIN Breast Cancer Committee chair Antonio Wolff tapped to co-lead the NCI Breast Cancer Steering Committee

March 20, 2024

Categories

Press Releases

Press Release: ARPA-H appoints Etta Pisano to lead its Advancing Clinical Trials Readiness Initiative

March 7, 2024

Categories

The March 2024 News from ECOG-ACRIN blog is now available

March 4, 2024

Categories

Press Releases

Press Release: NCI-MATCH cancer trial discovers a potentially broader role for an established dual HER2-blocking treatment

February 16, 2024

Categories

News Stories

AACR’s Clinical Cancer Research publishes a review article, “Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial”

February 9, 2024

Categories

The January/February 2024 News from ECOG-ACRIN blog is now available

Posts

ECOG-ACRIN Cancer Research Group Follow 7,811 6,283

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

; ECOG-ACRIN Cancer Research Group @eaonc ·

19h 1900600369664704974

March is #KidneyCancerAwarenessMonth! Learn about #ClinicalTrial EA8211/SOAR, a study testing a new treatment approach for patients with #KidneyCancer that has spread to 2-5 other places in the body. View more info here: https://www.youtube.com/watch?v=v29UtHNXkDs&t=8s cc: @KidneyCancerJ, @kidneycan

Reply on Twitter 1900600369664704974 Retweet on Twitter 1900600369664704974 0 Like on Twitter 1900600369664704974 0 Twitter 1900600369664704974

; ECOG-ACRIN Cancer Research Group @eaonc ·

20h 1900593200072437953

The EA3202 clinical study is comparing three possible treatment approaches for patients with advanced-stage #HeadAndNeckCancer to see which one helps patients live the longest. Learn more: https://bit.ly/ea3202-study #HNCA #HNCASM

Reply on Twitter 1900593200072437953 Retweet on Twitter 1900593200072437953 0 Like on Twitter 1900593200072437953 0 Twitter 1900593200072437953

; ECOG-ACRIN Cancer Research Group @eaonc ·

21h 1900578040058368065

The EAA173/DETER-SMM #ClinicalTrial is exploring new treatments for patients with high-risk #SmolderingMyeloma. Interested in learning more? Click here: https://bit.ly/eaa173detersmm cc: @nsc_natalie, @mtmdphd, @VincentRK, @NorthTxMSG

Reply on Twitter 1900578040058368065 Retweet on Twitter 1900578040058368065 1 Like on Twitter 1900578040058368065 1 Twitter 1900578040058368065

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).